ACRV
NASDAQAcrivon Therapeutics Inc.
$1.90-0.08 (-3.80%)
News25/Ratings11
Price$1.90-0.07 (-3.55%)
01:30 PM07:45 PM
News · 26 weeks53-64%
2025-10-262026-04-19
Mix3190d
- Insider15(48%)
- Other11(35%)
- SEC Filings5(16%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13D/A filed by Acrivon Therapeutics Inc.SCHEDULE 13D/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
- INSIDERDirector Ra Capital Management, L.P. was granted 3,888,888 shares (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERSEC Form 4 filed by Miller Mary4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- PRAcrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development OpportunitiesPotent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 (Topo 1) inhibition Data supports potential for frontline clinical combinations of ACR-368 and ACR-2316 with immune checkpoint inhibitors and of ACR-368 with Topo 1 antibody-drug conjugates (ADCs) WATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) pl
- PRAcrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)WATERTOWN, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced that the company approved a grant of equity award under its 2023 Inducement Plan to one employee. The equity award was granted in the form of stock options and has a grant date of April 15, 2026. The employee received an aggregate of options to purchase 111,150 shares of Acrivon c
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Acrivon Therapeutics Inc.SCHEDULE 13D/A - Acrivon Therapeutics, Inc. (0001781174) (Subject)
- SECSEC Form S-8 filed by Acrivon Therapeutics Inc.S-8 - Acrivon Therapeutics, Inc. (0001781174) (Filer)
- SECAcrivon Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
- PRAcrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business HighlightsMaturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC) Late-breaking oral presentation and corporate KOL panel at ESGO 2026 highlighted strong ACR-368 data in serous EC, a high unmet need subtype responsible for ~50% of EC mortality Initiated Arm 3 (ACR-368 + ultra low-dose gemcitabine) and adding Arm 4 (ACR-368) Phase 2b cohorts in all-comer (biopsy-independent) serous EC subjects Initial Phase 1 ACR-2316 data in AP3-prioritized solid tumor types showed favorable tolerability and promising clinical activity, notably in heavily pre-treated lung cancer subjects Cash, cash equivale
- SECSEC Form 10-K filed by Acrivon Therapeutics Inc.10-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
- PRAcrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint InhibitorsACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (ADCs) ACR-2316, a WEE1/PKMYT1 inhibitor currently in Phase 1, demonstrated complete and durable tumor regression in immunocompetent, syngeneic tumor mouse models in combination with anti-PD-L1 checkpoint inhibition WATERTOWN, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3
- INSIDERSEC Form 4 filed by Chief Accounting Officer Peterson Katharine4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERSEC Form 4 filed by Chief Legal Officer Miller Mary4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Mirza Mansoor Raza4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Levy Adam D.4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Devroe Eric4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERSEC Form 4 filed by Chief Development Officer Gamelin Erick4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERSEC Form 4 filed by President and CEO Blume-Jensen Peter4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- SECSEC Form 8-K filed by Acrivon Therapeutics Inc.8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
- SECAcrivon Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Acrivon Therapeutics, Inc. (0001781174) (Filer)
- INSIDERPresident and CEO Blume-Jensen Peter covered exercise/tax liability with 14,265 shares (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- PRAcrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care ConferenceWATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company's president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D., will participate in a fireside chat on Monday, March 2, 2026, at 1:50 p.m. ET at the TD Cowen 46th Annual Health Care Conference in Boston. The live and archived webcast of this event can be acces
- PRKey Opinion Leader (KOL) Panel to Discuss Acrivon's ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) CongressLive webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned gynecological oncology KOLs from the US and EU KOL panel to discuss maturing data from the ACR-368 registrational-intent trial, including recently disclosed promising results in serous EC, in the context of high unmet need in EC Panos Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute, professor, Harvard Medical School, will deliver late-breaking oral presentation of ACR-368 interim clinical data at the congress WATERTOWN, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology compa
- INSIDERChief Accounting Officer Peterson Katharine covered exercise/tax liability with 116 shares, decreasing direct ownership by 3% to 4,006 units (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)
- INSIDERChief Legal Officer Miller Mary covered exercise/tax liability with 217 shares, decreasing direct ownership by 0.64% to 33,679 units (SEC Form 4)4 - Acrivon Therapeutics, Inc. (0001781174) (Issuer)